The Pharmaletter

One To Watch

Tolerance Bio

A biopharma company focused on manipulating immune tolerance via the thymus to address various immune-mediated diseases.

Tolerance Bio is developing an allogeneic, thymus  induced pluripotent stem cell (iPSC)-based cell therapy platform as well as pharmacological thymus therapies to address immune-mediated diseases caused by abnormalities in immune tolerance, including cancer, autoimmunity, transplant rejection, infections, immune deficiencies, and allergies.

Want to Update your Company's Profile?


Latest Tolerance Bio News

More Tolerance Bio news >